



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :  C12N 15/00	A1	(11) International Publication Number: WO 89/10404  (43) International Publication Date: 2 November 1989 (02.11.89)
<p>(21) International Application Number: PCT/GB89/00401</p> <p>(22) International Filing Date: 18 April 1989 (18.04.89)</p> <p>(30) Priority data: 8809129.3 18 April 1988 (18.04.88) GB</p> <p>(71) Applicant (for all designated States except US): CELLTECH LIMITED [GB/GB]; 216 Bath Road, Slough SL1 4EN, Berkshire SL1 4EN (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BEBBINGTON, Christopher, Robert [GB/GB]; 20C Trinity Place, Windsor, Berkshire SL4 3AT (GB). YARRANTON, Geoffrey, Thomas [GB/GB]; 8 Sherwood Road, Winnersh, near Reading, Berkshire RG11 5NJ (GB).</p> <p>(74) Agent: MERCER, Christopher, Paul; Carpmaels &amp; Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AU, JP, US.</p> <p>Published With international search report.</p>
<p>(54) Title: RECOMBINANT DNA METHODS, VECTORS AND HOST CELLS</p> <p>(57) Abstract</p> <p>The present invention relates to a method for transforming a lymphoid cell line to glutamine independence which comprises: transforming the lymphoid cell line with a vector containing an active glutamine synthetase (GS) gene; growing the transformed cell line on a medium containing glutamine; and continuing the growth of the transformed cell line on a medium in which the glutamine is progressively depleted or on a medium lacking glutamine, and to vectors and host cells for use in the method.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

Recombinant DNA Methods, Vectors and Host Cells

The present invention relates to methods for improving the usefulness of lymphoid cell lines as host cells for the production of proteins by recombinant DNA technology. The present invention also relates to vectors for use in such methods and to host cells produced by such methods.

Lymphoid cell lines are at present being appraised for use as host cells in the production by recombinant DNA technology of immunoglobulin molecules, related hybrid or chimeric proteins (Ig-type molecules), or other recombinant proteins. Since the lymphoid cells include myeloma cells which are of the same general type as the B cells which produce Ig molecules in vivo, it is envisaged that they will naturally possess the intracellular mechanisms necessary to allow proper assembly and secretion of Ig-type molecules. Such lymphoid cell lines may also be of use in the production by recombinant DNA technology of non-Ig-type molecules.

It is known that many lymphoid cell lines, such as myeloma cell lines and T cell lymphomas, cannot be grown in vitro on media lacking in glutamine. It has been suggested that it would be useful to be able to transform lymphoid cell lines to glutamine independence, since this may provide an advantageous method for selecting transformed cell lines.

It has been conjectured that such a cell line could be transformed to glutamine independence by incorporating therein a gene coding for glutamine synthetase (GS). Such a suggestion is made in EP-A-0 256 055 (Celltech). However, it has subsequently been found that hybridoma cell lines can generate spontaneous variants able to grow in a glutamine-free medium at such a high frequency that the identification of transfectants is difficult or impossible. For myeloma cell lines, transfection with a GS gene and growth of the transformed cells in a glutamine-free medium does not result in significant survival rates.

It is therefore an object of the present invention to provide a method for transforming lymphoid cell lines to

glutamine independence.

According to the present invention, there is provided a method for transforming a lymphoid cell line to glutamine independence which comprises:

- 5 transforming the lymphoid cell line with a vector containing an active glutamine synthetase (GS) gene;

growing the transformed cell line on a medium containing glutamine; and

- continuing the growth of the transformed cell line on a  
10 medium in which the glutamine is progressively depleted or on a medium lacking glutamine.

Preferably, the lymphoid cell line is a myeloma cell line.

- Preferably, the glutamine-depleted or glutamine-free  
15 medium contains asparagine. Alternatively the medium contains another nutrient which enables the transformed cell line to survive on a glutamine free medium. This other nutrient may be an ammonia donor, such as ammonium chloride.

- It has surprisingly been found that if the transformed  
20 lymphoid cell line is not firstly grown on a glutamine-containing medium, it is not possible to obtain the growth of any cell line, whether or not it has been transformed by the vector. By use of the method of the present invention, it is possible to select for lymphoid cell lines which have  
25 been transformed by the vector.

- Alternatively, the lymphoid cell line may be transformed with a vector containing both an active GS gene and a gene encoding another selectable marker, such as a gpt gene, or  
cotransformed with separate vectors encoding GS and the  
30 selectable marker respectively. Transformed host cells can then be selected using the selectable marker prior to depletion of glutamine in the medium.

- The advantage of this method is that it enables selection for vector maintenance to be achieved without the use of a  
35 toxic drug. Host cells in which the vector is eliminated will not be able to survive in a glutamine-free medium.

A further advantage of this method is that it enables selection for gene amplification to be carried out without

the risk of amplification of the host cell's endogeneous GS genes.

Preferably the glutamine in the medium is progressively depleted by dilution with a medium containing asparagine but  
5 lacking glutamine.

Preferably, the vector used to transform the lymphoid cell line also contains an active gene coding for a protein heterologous to the lymphoid cell line. Alternatively, the lymphoid cell line may be co-transformed with a separate  
10 vector containing the active gene coding for the heterologous protein.

The heterologous protein may be one which is expressed as a single chain (although it may be cleaved after expression into a multichain protein). Examples of such  
15 single chain expression products are tissue plasminogen activator (tPA), human growth hormone (hGH) or tissue inhibitor of metalloproteinase (TIMP).

Preferably, however, the heterologous protein is an Ig-type molecule. Such molecules require the separate  
20 expression of two peptide chains which are subsequently assembled to form the complete molecule. Thus, the cell line will need to be transformed with active genes which encode separately a heavy chain (or heavy chain analog) and a light chain (or light chain analog).

Preferably, the genes encoding the heavy and light chains  
25 are both present on the same vector as the GS gene. Alternatively, the vector containing the GS gene may have one of the heavy or light chain genes thereon, the other gene being on a separate vector. In a second alternative,  
30 the light and heavy chain genes are not present on the vector containing the GS gene but are present on the same or different vectors.

The expression of such heterologous proteins may be substantially increased by subsequent selection for GS gene  
35 amplification, for instance using methionine sulfoximine (MSX) as the selection agent.

It is preferred that the GS gene comprises a relatively weak promoter and that the gene (or genes) encoding the

heterologous protein comprises a relatively strong promoter so that in the transformed cell lines, protein synthesis is directed preferentially to the production of the heterologous protein or peptide rather than to the  
5 production of GS. Moreover, a lower concentration of selection agent, such as MSX, will be required to select for gene amplification if the GS gene is controlled by a weak, rather than a strong, promoter.

It is also conjectured that use of a weak promoter may  
10 enable the selection of transformed cell lines wherein the GS gene has been inserted at a particularly advantageous location in the genome. This will ensure that both the GS gene and any heterologous genes will be transcribed efficiently.

15 It has been found that, in the preferred case, where all the genes are present on the same vector, it is necessary to design the vector carefully in order to achieve proper expression of the genes.

Thus, according to a second aspect of the present  
20 invention, there is provided a vector for transforming a lymphoid cell line to glutamine independence and to enable it to produce a heterologous protein, the vector comprising a GS gene and a gene encoding the heterologous protein, wherein the vector is arranged such that expression of the  
25 GS gene is not hindered by transcriptional interference from the promoter/enhancer transcribing the sequence coding for the heterologous protein to such an extent that glutamine-independent colonies cannot be produced.

Preferably, the genes on the vector are arranged in such  
30 orientations and with such promoters as substantially to prevent transcriptional interference. For instance, the GS gene may contain a relatively weak promoter, the gene encoding the heterologous protein may contain a relatively strong promoter, and the promoter of the GS gene may be  
35 located upstream of or may direct expression in the opposite direction to that of the gene encoding the heterologous protein.

It has surprisingly been found that if the vector

arrangement set out above is adopted, the GS gene is expressed in sufficient quantity to enable selection to be made and the heterologous protein is expressed more efficiently than with other vector arrangements.

5 It has been observed that other vector arrangements, for instance using different promoters or a different ordering or orientation of the genes, can lead to a much reduced or even non-existent level of GS or heterologous protein production. It is conjectured (although the applicants do  
10 not wish to be limited to this theory) that if a gene containing a strong promoter is located upstream of a GS gene having a weaker promoter, the transcription of the upstream gene will run through into the downstream gene, thus producing occlusion of the downstream promoter. Since  
15 the frequency of transformed colonies is critically dependent on the level of GS gene expression, such promoter occlusion dramatically reduces the frequency with which transfectants are recovered.

A preferred combination for the weak and strong  
20 promoters is the SV40 early region and the hCMV-MIE promoters. (hCMV-MIE = human cytomegalovirus major immediate early gene). However, other suitable promoter combinations will be readily apparent to those skilled in the art.

A particularly preferred embodiment of the vector of the  
25 present invention comprises a GS gene having a weak promoter having downstream therefrom a heavy chain-like gene having a strong promoter, there being on the vector a light chain-like gene having a strong promoter oriented in the opposite direction to the promoters of the GS and heavy chain-like  
30 genes.

Alternatively, promoter occlusion may be prevented by use of transcription terminator signals between the genes.

In another alternative, the genes may be arranged with a unique restriction site between them. This site can then  
35 be used to linearise the vector before it is incorporated into the host cell. This will ensure that in the transformed host cell no promoter occlusion can take place.

It will be appreciated that if the vector contains more

than one gene encoding a heterologous protein, it will be necessary to ensure that none of the genes in the vector can promote transcriptional interference. For instance, if the vector contains a GS gene, a heavy chain gene and a light  
5 chain gene, it is preferred that either all three genes are transcribed in the same direction and that the GS gene is upstream of the other two genes or that the GS gene and one of the other genes are transcribed in the same direction, the GS gene is upstream of the first other gene, and the  
10 second other gene is transcribed in the other direction, and the promoter of the second other gene is located adjacent the promoter of the GS gene.

The vector may comprise a viral vector, such as lambda phage, or a plasmid vector, for instance based on the well  
15 known pBR322 plasmid. However, any other of the vectors well known in the art may be adapted by use of conventional recombinant DNA technology for use in the present invention.

The present invention also includes host cells produced  
20 by the method of the invention or containing vectors according to the invention.

In particular, the present invention includes a lymphoid cell line which has been cotransformed with a vector containing a GS gene and a vector containing a gene encoding  
25 a heterologous protein, the vectors being arranged to ensure that the GS gene is not hindered by transcriptional interference to such an extent that glutamine-independent colonies cannot be produced.

The present invention is described below by way of  
30 example only with reference to the accompanying drawings in which:

Figure 1 shows an analysis of proteins secreted by NSO cells transfected with plasmid pAB2GS by Western blotting in which 25 $\mu$ l of culture supernatant or control tissue culture  
35 medium was run on a 10% SDS reducing polyacrylamide gel, blotted onto nitro-cellulose and probed with antisera recognising human Ig chains and then with <sup>125</sup>I-labelled protein A;



Figure 2 shows the structure of plasmid pSV2GSCLc;  
Figure 3 shows the structure of plasmid pST6; and  
Figure 4 shows a Southern blot analysis of genomic DNA  
from cell lines SV2GSNSO and CMGSNSO.

- 5        In Figure 1 of the drawings lane 1 shows purified  
chimeric B72.3 antibody to show the position of Ig light and  
heavy chains, lanes 2 to 5 show culture supernatants from  
four different transfected clones, and lane 6 shows culture  
medium as a negative control.
- 10      In Figure 2, E is the SV40 early region promoter, GS is a  
GS cDNA coding sequence, intron + PA is the small t-intron  
and the early region polyadenylation signal of SV40, hCMV is  
the hCMV-MIE promoter-enhancer, cLc is the coding sequence  
for the chimeric L-chain of a humanised antibody known as  
15 B72.3, and pA is the SV40 early polyadenylation signal.

20        In Figure 3, hCMV is the hCMV-MIE promoter enhancer (2.1  
kb) fragment. CHC is the chimeric heavy chain coding  
sequence of the B72.3 antibody. CLC is the chimeric light  
chain coding sequence of the B72.3 antibody. Poly A  
contains the SV40 early polyadenylation signal. I + PA  
contains the small t intron of SV40 and the early region  
polyadenylation signal. SVE is the SV40 early promoter. A  
bacterial plasmid origin of replication and ampicillin  
resistance gene are provided by pBR322.

- 25        Figure 4 shows a copy number analysis of GS-vectors in  
NSO cells before and after selection with MSX. DNA samples  
were digested with BglI and BglII, electrophoresed on a 1%  
agarose gel, transferred to nitrocellulose and probed with  
the 0.5 kb 5' PstI DNA fragment of pGSC45 [11] isolated from  
30 a GS cDNA.

DNA samples are as follows:-

- |           |   |
|-----------|---|
| Lane 1    | plasmid pSV2GS equivalent to 100 copies/cell    |
| Lane 2    | plasmid pSV2GS equivalent to 10 copies/cell     |
| 35 Lane 3 | plasmid pSV2GS equivalent to 1 copy/cell        |
| Lane 4    | 10µg NSO genomic DNA                            |
| Lane 5    | 10µg SV2GSNSO genomic DNA                       |
| Lane 6    | 10µg SV2GSNSO (100µM MSX resistant) genomic DNA |

- Lane 7        plasmid pCMGS equivalent to 100 copies/cell  
Lane 8        plasmid pCMGS equivalent to 10 copies/cell  
Lane 9        plasmid pCMGS equivalent to 1 copy/cell  
Lane 10       10 $\mu$ g CMGSNSO genomic DNA  
5 Lane 11     10 $\mu$ g CMGSNSO (100 $\mu$ M MSX resistant) genomic DNA  
m.w.         $\lambda$  phage DNA digested with ClaI; molecular weight  
             markers.

A list of references is given at the end of the  
10 description. In the following, the references are indicated  
by numbers enclosed in square brackets.

#### VECTORS

- 15        In the following Examples, for comparative purposes, two  
         plasmids described in EP-A-0 256 055 were used. These are  
         plasmids pSVLGS1 and pSV2GS. Plasmid pSVLGS1 contains a GS  
         minigene, containing cDNA and genomic DNA sequences, under  
         the control of a SV40 late region promoter. Plasmid pSV2GS  
20        contains a cDNA sequence encoding GS under the control of a  
         SV40 early region promoter.

A vector pSV2BamGS was produced by converting the unique  
PvuII site in pSV2GS to a BamHI site by the addition of a  
synthetic oligonucleotide linker.

- 25        By use of synthetic oligonucleotide linkers, the major  
         immediate early gene promoter, enhancer and complete 5'-  
         untranslated sequence from human cytomegalovirus (hCMV-MIE)  
         (the Pst-1m fragment [1] together with a synthetic  
         oligonucleotide to recreate the remaining 5' untranslated  
30        sequence) was inserted between the NcoI sites of pSV2GS such  
         that the hCMV-MIE promoter directs expression of the GS  
         coding sequence. The resulting plasmid was labelled pCMGS.

Plasmid pSV2BamGS was digested with BamHI to give a 2.1kb  
fragment containing the transcription cassette.

- 35        For convenient construction of other expression plasmids,  
         a basic vector pEE6 was used. Plasmid pEE6 contains the  
         XmnI to BclI fragment of plasmid pCT54 [2] with the  
         polylinker of plasmid pSP64 [3] inserted between its HindIII

and EcoRI sites but with the BamHI and Sall sites removed from the polylinker. The BclI to BamHI fragment is a 237bp SV40 early gene polyadenylation signal (SV40 nucleotides 2770-2533). The BamHI to BglI fragment is derived from  
5 plasmid pBR322 [4] (nucleotides 275-2422) but with an additional deletion between the Sall and AvaI sites (nucleotides 651-1425) following addition of a Sall linker to the AvaI site. The sequence from the BglI site to the XmnI site is from the  $\beta$ -lactamase gene of plasmid pSP64 [3].

10 Plasmid pEE6gpt contains the transcription unit encoding xanthine-guanine phosphoribosyl transferase (gpt) from plasmid pSV2gpt [5] cloned into plasmid pEE6 as a BamHI fragment by the addition of a BamHI linker to the single PvuII site of plasmid pSV2gpt.

15 By similar means, a derivative of plasmid pCMGS containing the transcription cassette for the xanthine-guanine phosphoribosyl transferase (gpt) gene from pEE6gpt was produced. The plasmid thus produced was labelled pCMGSgpt.

20 Plasmid pEE6hCMV contains the hCMV-MIE promoter- enhancer and complete 5' untranslated sequence inserted by means of oligonucleotide linkers into the HindIII site of plasmid pEE6.

Plasmid pEE6hCMVBglII is a derivative of pEE6hCMV in  
25 which the HindIII site upstream of the hCMV enhancer has been converted to a BglII site by blunt-ending and addition of a synthetic oligonucleotide linker.

Plasmid pEE6HCLCBg is a vector derived from pEE6hCMV containing a coding sequence for a mouse-human chimeric Ig  
30 light chain from the B72.3 antibody [6] inserted into the EcoRI site of pEE6hCMV such that the light chain is under the control of the hCMV-MIE promoter-enhancer. (The upstream HindIII site has also been converted to a BglII site by standard methods.) The 2.1 kb BamHI fragment from pSV2BamGS  
35 was inserted into pEE6HCLCBg to produce a plasmid pCLc2GS in which the Ig light chain and GS genes are transcribed in the same orientation with the GS gene downstream of the light chain gene.

pEE6HCHHCL is a vector which contains sequences coding for both the heavy and light chains of the chimeric B72.3 antibody [6] under the control of hCMV-MIE promoter enhancers. The 2.1 kb BamHI fragment from pSV2BamGS was inserted into pEE6HCHHCL to produce a plasmid pAb2GS in which the heavy and light chain genes and the GS gene are all transcribed in the same orientation in the order heavy chain, light chain, GS.

A 3.1 kb BglII-BamHI fragment from pEE6HcLcBg was inserted into the BamHI site of pSV2GS to produce a plasmid pSV2GSCLc in which the chimeric light chain gene and the GS gene are transcribed in the same orientation with the GS gene upstream of the light chain gene.

Similarly, the 3.1 kb BglII-BamHI fragment of PEE6HCLCBg was inserted into the BamHI site of pCMGS to produce a plasmid pCMGS.CLC in which both genes are again in the same orientation.

pEE6CHCBg is a plasmid containing the heavy chain gene of chimeric B72.3 antibody [6] under the control of the hCMV-MIE promoter-enhancer and SV40 polyadenylation signal. The hCMV-MIE chain termination unit was excised from the plasmid as a 4.7 kb partial HindIII - BamHI fragment and inserted, by means of a HindIII - BamHI oligonucleotide adaptor, at the single BamHI site of pSV2GSCLc to form pSV2GSCLcchc. The BamHI site upstream of the hCMV-MIE-CH chain transcription unit in pSV2GSCLcchc was then removed by partial BamHI digestion, filling in with DNA polymerase I and religating to form pST6.

A gene coding for a novel fibrinolytic enzyme of 90 kD molecular weight was isolated as a 2.8 kb HindIII to BglII fragment. This was then inserted between the HindIII and BclI sites of the expression plasmid pEE6hCMVBglII in the appropriate orientation such that the hCMV promoter directed transcription of the inserted gene. An SV40 Early-GS transcription unit was excised as a BamHI fragment from pSV2GS and inserted into the BglII site at the 5' end of the hCMV sequence in pEE6hCMVBglII, in the appropriate orientation such that transcription from the hCMV promoter

and the SV40 early promoter is in the same direction. This formed the plasmid pEE690KGS.

### Cell Lines

5

In the Examples, the following cell lines were used: NSO and P3-X63Ag8.653, which are non-producing variants of the mouse P3 mouse plasmacytoma line; Sp2/0, which is a non-producing mouse hybridoma cell line; and YB2/0, which is a non-producing rat hybridoma cell line.

### Media

All cells were grown in either non-selective medium, Dulbecco's Minimum Essential Medium (DMEM) containing 2mM glutamine, 100  $\mu$ M non-essential amino acids, 10% foetal calf serum and streptomycin/penicillin, or in glutamine-free DMEM (G-DMEM) containing 500  $\mu$ M each of glutamate and asparagine, 30  $\mu$ M each of adenosine, guanosine, cytidine and uridine, 10  $\mu$ M thymidine, 100  $\mu$ M non-essential amino acids, 10% dialysed foetal calf serum and streptomycin/penicillin, or in derivatives of G-DMEM lacking various of these additives.

Alternatively, cells were cultured in gpt-selective media, made using the following filter-sterilised stock solutions: 1) 50x each of hypoxanthine and thymidine; 2) 50x xanthine (12.5 mg/ml in 0.2 M NaOH); 3) mycophenolic acid (MPA, 250  $\mu$ g/ml in 0.1 M NaOH); and 4) 1M HCl. gpt-selective medium is made by mixing 93 ml of non-selective medium (described above), 2ml solution 1), 2 ml solution 3), and 0.6 ml solution 4). 2x gpt is made by mixing 86 ml of non-selective medium with twice the above quantities of solutions 1) to 4).

### Linearisation of Plasmids

35

In order to introduce them into cells all plasmids were linearised by digestion with an appropriate restriction enzyme which cuts at a single site in the plasmid and hence

does not interfere with transcription of the relevant genes in mammalian cells. Typically 40  $\mu$ g of circular plasmid was digested in a volume of 400  $\mu$ l restriction buffer. The enzymes used for linearisation of the plasmids are shown in Table 1.

TABLE 1

Enzymes used for Linearisation of Plasmid

10

<u>Plasmid</u>	<u>Restriction Enzyme</u>
pSVLGS.1	PvuI
pSV2.GS	PvuI
15 pSV2.Bam GS	PvuI
PCMGS	PvuI
PCMGS.gpt	PvuI
PEE6.gpt	SalI
pCLc2GS	SalI
20 pAb2GS	SalI
pSV2.GScLc	TthIII
PCMGS.cLc	TthIII
pST6	BamHI
pEE690KGS	SalI

25

Electroporation of Cells

Cells were harvested while growing exponentially, washed once in phosphate-buffered saline (PBS) by centrifugation at 30 1200 rpm in a bench centrifuge and resuspended at a density of  $10^7$  cells/ml in fresh ice cold PBS. One ml of cell suspension was added to the digested plasmid DNA (0.4 ml in restriction buffer) and incubated on ice for 5-10 minutes. The cell-DNA mixture was then subjected to 2 pulses of 2000 35 volts between aluminium electrodes spaced approximately 1 cm apart using a conventional electroporation apparatus having a capacitance of 14  $\mu$ F. Cells were then returned to ice for 5-10 minutes, resuspended in non-selective growth medium

(DMEM) and distributed among 24-well culture trays. Selective medium (G-DMEM) was added subsequently as described below.

#### 5 EXAMPLE 1

Preliminary experiments indicated that the plasmid pSVLGS1 which has been used successfully as a selectable marker in CHO-K1 cells (see EP-A-0 256 055) could not be  
10 introduced into NSO cells to confer glutamine independent growth at efficient rates. Only a very low frequency of approximately 6 transfected colonies per  $10^7$  cells was obtained. This should be compared with the transfection frequencies in excess of  $1/10^4$  transfected cells which are  
15 obtained using the xanthine-guanine phosphoribosyl transferase (gpt) selectable marker gene from pEE6gpt and selecting for resistance to mycophenolic acid in medium containing xanthine, hypoxanthine and thymidine. Preliminary experiments using pCMGS, in which the GS cDNA is  
20 expressed from the hCMV-MIE promoter yielded a much higher frequency of glutamine-independent colonies and pSV2GS, which utilises the SV40 early region promoter, yielded an intermediate transfection frequency.

In order to establish a suitable protocol for  
25 consistent use in selection, 20  $\mu$ g linearised pCMGS and 20  $\mu$ g of linearised pEE6gpt were mixed and introduced together into  $10^7$  NSO cells. A separate aliquot of  $10^7$  cells was "mock" transfected by electroporation without added DNA.

The cells were plated in 24-well plates as described  
30 above in 0.5 ml non-selective medium (DMEM) and 24 hours later, selection was applied to wells of the "mock" and DNA transfected plates as follows:-

A added 1 ml G-DMEM and left for 7 days before examining  
35 plates.

B added 1 ml G-DMEM on day 1, aspirated on day 2 and replaced with fresh G-DMEM.

C added 1 ml G-DMEM containing 200  $\mu$ M glutamine on day 1, left for 2 more days then aspirated and replaced with G-DMEM.

5

D left on day 1 and added 1 ml G-DMEM on day 2. On day 3, medium was aspirated and replaced with fresh G-DMEM.

E left on day 1 and aspirated on day 2 and replaced with 10 1 ml G-DMEM. The wells were aspirated again on day 4 and replaced with fresh G-DMEM.

F mycophenolic acid selection: added 0.5 ml gpt-selective medium and on day 2 added 0.5 ml of 2x gpt-selective medium. 15

The number of surviving colonies in each of at least 3 wells for each selective protocol was scored 7-10 days after transfection and the mean results are shown in Table 2.

20

TABLE 2

	Selective Protocol	Mean No. colonies/ $10^6$ cells plated	
		MOCK	PCMGS + pEE6gpt
25	A	0	130
	B	0	3
	C	0	72
	D	0	8
	E	0	8
30	F	0	115

From these results it appears that protocol A (addition of 1 ml G-DMEM one day after transfection) provides the highest survival of transfected colonies and the frequency 35 obtained when selecting for the introduced GS gene is equal to the transfection efficiency measured by selection for the gpt gene (Protocol F). Addition of a small amount of glutamine and aspiration after 2 more days, to replace with



G-DMEM alone, (protocol C) provides the next highest frequency of glutamine independent colonies. However, removing the medium by aspiration and hence complete removal of glutamine (protocols B, D and E) severely reduces the number of surviving colonies. It can thus be seen that progressive depletion of glutamine in the medium leads to an enhanced selection procedure. Therefore protocol A was used in all subsequent experiments.

A strong promoter such as the hCMV-MIE promoter is likely to provide a high level of GS expression and hence will require a high level of MSX to select for gene amplification.

In order to determine whether a weaker promoter than the hCMV-MIE promoter-enhancer can be used to express a GS cDNA to obtain glutamine-independent transformants, 40  $\mu$ g linearised pSV2BamGS, which uses the SV40 Early region promoter for GS expression, was introduced into NSO cells and selected using Protocol A. The results are shown in Table 3.

TABLE 3

DNA Transfected	Selection Protocol	Mean No. Colonies/ $10^6$ Cells
20 $\mu$ g pCMGS	A	100
20 $\mu$ g pEE6gpt	F	40
30 40 $\mu$ g pSV2BamGS	A	20
"Mock"	A	0

Thus it appears that the GS-transcription unit in pSV2BamGS can indeed be used as a selectable marker in NSO cells but confers glutamine independence at a lower frequency than does pCMGS.

In order to test whether the GS gene in pSV2BamGS can be used as a selectable marker for the introduction of

heterologous DNA into NSO cells, three different plasmids were constructed which contain different non-selectable linked genes all under the control of the hCMV MIE promoter-enhancer. These are pCLc2GS, which contains the chimeric  
5 B72.3 immunoglobulin light-chain gene; pTIMPGS, which contains the gene for tissue inhibitor of metalloproteinase (TIMP); and pAb2GS which contains both heavy and light chain genes for the chimeric B72.3 monoclonal antibody. Each was introduced into NSO cells as a linear plasmid using 40  $\mu$ g of  
10 pCLc2GS and pTIMPGS and 80  $\mu$ g of pAb2GS per  $10^7$  cells transfected. The transfection frequency was  $4/10^7$  cells for pAb2GS and no colonies were obtained with either of the other two plasmids. The 4 colonies obtained from  
15 transfection with pAb2GS were grown in bulk culture and spent culture supernatant analysed by Western blotting using anti-heavy and anti-light chain antibodies. The result is shown in Figure 1. It is clear that all 4 clones secrete both heavy and light chains but at very low level (undetectable by enzyme-linked immunosorbent assay). Thus  
20 the GS-transcription unit from pSV2BamGS can be used as a selectable marker to introduce heterologous genes into NSO cells but the presence of such genes in these particular plasmid constructions seems to reduce substantially the frequency with which transfected colonies can be isolated.  
25 It is likely that this is due to an interference between the various transcription units on the plasmid. Hence only those few colonies in which the genes upstream of the GS-transcription unit are for some reason exceptionally poorly expressed, can yield sufficient GS for survival.  
30 In order to test whether the position of genes on the vector was indeed responsible for the dramatic reduction in frequency of transformation to glutamine-independent growth, plasmids were constructed in which the GS gene transcription is upstream of a cL chain gene instead of downstream as in  
35 the previous experiments. The two plasmids chosen were pCMGScLc and pSV2GScLc, in which the GS gene is under the control of the hCMV-MIE promoter. These plasmids were introduced into NSO cells and transfectants selected using

Protocol A. The number of colonies obtained is shown in Table 4.

Table 4.

5	Plasmid	No. Colonies/ $10^6$ cells
	pCMGS	250
	pCMGS.cLc	300
	pSV2.GS	18
10	pSV2GS.cLc	9
	pCLc2GS	0

These results show that whereas pCLc2GS, in which the GS gene is downstream of the cLc gene, yields no glutamine-independent colonies, the equivalent plasmid, pSV2GS.cLc, which has the gene order reversed, with the GS gene upstream, yields a transformation frequency comparable to that obtained using the GS gene alone (pSV2GS).

This study suggests that any interference of the SV40 early promoter used to express GS is reduced by placing the strong hCMV-MIE promoter downstream. The results in Table 4 also show no significant difference in the transformation efficiency obtained with pCMGS.cLc compared with pCMGS, again indicating no interference with GS expression.

The transfectants obtained with plasmids pCMGS.cLc and pSV2GS.cLc were assayed for cL chain secretion using an ELISA assay for human kappa chain antigen activity in spent culture medium. All culture wells from the pCMGS.cLc transfection, each containing many transfected colonies, did indeed secrete significant amounts of antigen. Seven out of ten wells from the pSV2GS.cLc transfection, again containing multiple colonies, also secreted detectable levels of light chain.

This is marked contrast to the results obtained with plasmids in which the GS gene is downstream of the second gene controlled by the hCMV-MIE promoter and demonstrates that the GS gene can be used as an effective selectable marker in this cell type, provided that the plasmid is

appropriately designed.

psv2GS is a particularly suitable vector into which heterologous genes may be inserted and psv2GSclC is shown in Figure 2.

- 5 In order to test which of the additives present in G-DMEM is essential for the growth of GS transfectants, pooled transfected cells containing the plasmid pCMGScLc were distributed among wells of a 24 well tissue culture tray in DMEM with 10% dialysed foetal calf serum and containing all  
10 possible combinations of the following additives at the concentrations present in G-DMEM: a) non- essential amino acids; b) glutamate; c) asparagine; d) adenosine, guanosine, cytidine, uridine and thymidine. Growth was scored after four days and the results are shown in Table 5.

15

Table 5

	Medium Additions	Growth
20	None	-
	abcd	++
	abc	++
	abd	++
	ab	++
25	ac	++
	ad	++
	a	++
	b	-
	bc	++
30	bd	-
	bcd	++
	c	++
	cd	++
	d	-
35	bx4	-

From this it is clear that 500  $\mu$ M asparagine is sufficient to sustain growth of GS transfectants in the

absence of any other of the additives in G-DMEM. Surprisingly, glutamate, the substrate for GS, will not sustain growth of these cells, even when the concentration is raised to 2mM. Non-essential amino acids can be used  
5 instead of 500  $\mu$ M asparagine to support growth of these transfectants, but as this additive contains 100  $\mu$ M asparagine, it is possible that this concentration of asparagine alone is sufficient to support growth.

It is clear that the NSO cell line must contain  
10 insufficient active GS-enzyme to permit growth in the glutamine-free medium used here and that a plasmid such as pCMGS yields sufficient GS when expressed in these cells to allow glutamine independent growth. Clones expressing a GS gene under the control of a weaker promoter, such as the  
15 SV40 Early promoter, on average express less GS enzyme and only a proportion of transfectants can survive in the glutamine-free medium.

In order to test whether GS-vectors can be used to confer glutamine-independent growth on other lymphoid cell  
20 lines, the growth of three additional cell lines in glutamine-free media was investigated. P3-X63Ag8.653 (a mouse myeloma) was also found to be completely incapable of growth in G-DMEM. When  $10^7$  cells were plated out in a 24-well plate and selected using Protocol A, no glutamine  
25 independent variants were isolated. In contrast the non-secreting mouse hybridoma SP2/0 generated variants able to grow in G-DMEM at a frequency of approximately  $1/10^5$  cells plated. Since the transfection frequency in this cell line (eg using pEE6gpt) is also about  $1/10^5$  cells plated, this  
30 cell line is unsuitable as a host for GS selection using this protocol.

The rat non-secreting hybridoma YB2/0 also yielded glutamine-independent variants at an even higher frequency, estimated at  $1/10^2$ , making this cell line unsuitable for  
35 use with the GS-selection protocol developed above. A glutamine-independent variant of YB2/0 was cloned and a clonal cell line, designated YOG- F10, was grown in bulk culture and stored as frozen stocks in liquid nitrogen. A

similar cloned cell line, a glutamine-independent variant of SP2/0, termed SPG2-E4 was also stored in liquid nitrogen. Such cell lines will be suitable for the introduction of vectors containing GS genes by methods described in EP-A- 0 5 256 055.

In order to test whether selection for glutamine-independent transformants can be used to introduce plasmid vectors into P3-X63Ag8.653 cells, 40 µg linear pCMGSgpt (a vector containing both the GS-transcription unit from pCMGS and the gpt gene from pEE6gpt) was introduced by electroporation into 10<sup>7</sup> P3-X63Ag8.653 cells. The results are shown in Table 6.

TABLE 6

15

Transfection of P3-X63-Ag8.653

PLASMID	SELECTION PROTOCOL	NO. COLONIES/10 <sup>6</sup> CELLS
pCMGS.gpt	A	120
	F	24
"Mock"	A	0
	F	0

Thus the hCMV-GS transcription unit and selection Protocol A chosen for NSO cells can be used to obtain glutamine-independent P3-X63Ag8.653 at a frequency which is at least as great (possibly higher) than obtained using gpt selection. It should be noted that interference ("promoter occlusion") between the two transcription units could account for the lower frequency at which gpt-selected colonies arise.

The myeloma cell lines NSO and P3-X63Ag8.653 have been successfully transformed to glutamine independent growth by transfection with GS-expression plasmids. In contrast, two

hybridoma lines, YB2/0 and SP2/0 generate glutamine-independent variants at too high a frequency for GS-plasmids to be used in this way as selectable markers in these cells. It is also demonstrated here that a GS-expression plasmid  
5 such as pSV2GS can be used to introduce non-selected genes such as the genes encoding the B72.3 chimeric antibody into NSO cells. The arrangement of genes on the plasmid have marked effects on the expression levels attained from these genes and it will be important to take this into account in  
10 the design of optimal expression vectors. Transcription from a strong promoter such as the hCMV-MIE promoter-enhancer should not be permitted to proceed towards a gene expressed from a weaker promoter, such as the SV40 Early promoter unless the two genes are separated, e.g. by a  
15 transcription termination signal.

#### EXAMPLE 2

In order to confirm that the GS-transcription units in  
20 plasmids such as pCMGS and pSV2BamGS can act as amplifiable selectable markers in a myeloma cell line, the copy number of vector DNA introduced into NSO cells by electroporation was analysed before and after selection for GS-gene amplification using methionine sulfoximine (MSX).

25 NSO cells were transfected with pSV2BamGS or pCMGS as described above and pools of transfected colonies (at least 20 colonies from each transfection) were expanded in culture to form cell lines SV2GSNSO and CMGSNSO. These two cell pools were then distributed among the wells of a 24-well  
30 cell culture tray at a cell density of approximately  $10^5$  cells/well in G-DMEM medium. MSX was added to the wells to final concentrations ranging between 20 and  $80\mu\text{M}$ . After incubation for several days, extensive cell death was observed in all wells and, after 2-3 weeks, MSX-resistant  
35 colonies were visible at concentrations of MSX up to  $60\mu\text{M}$  for the SV2GSNSO cell line and up to  $80\mu\text{M}$  for the CMGSNSO cell line. Cells isolated at these concentrations of MSX were replated at approximately  $10^5$  cell/well in 24-well

trays and selection reapplied at concentrations up to 100 $\mu$ M. In both cases there was considerable cell survival at 100 $\mu$ M. 100 $\mu$ M MSX-resistant cell pools were expanded in culture and total genomic DNA prepared from initial transfectants and  
5 from cell pools resistant to 100 $\mu$ M MSX.

DNA samples were digested with BglI and BglII restriction enzymes and a Southern blot of the DNA samples was probed with the 0.5 kb 5' PstI GS-cDNA fragment from pGSC45 [7]. The Southern blot analysis is shown in Figure 3. The DNA  
10 probe cross-hybridises with the endogenous mouse GS-gene in NSO cells and this is seen as a fragment of approximately 2.8kb and one of approximately 6kb in all transfected cell lines, as well as in non-transfected NSO control DNA. These bands serve as an internal control for loading of the same  
15 amount of DNA in each track on the gel. In cells transfected with pSV2BamGS, a 1.2kb BglII fragment is also detected, which is of the size predicted for vector DNA (from a BglI site in the SV40 promoter to the BglII site at the 3' end of the GS cDNA). By comparison with known  
20 amounts of vector DNA loaded in adjacent tracks, the average vector copy number in the SV2GSNSO pool is estimated to be approximately 1 copy/cell. After selection in 100 $\mu$ M MSX, the copy number is increased to an average of about 5 copies/cell.

25 Similarly, introduction of pGMGS into NSO cells has led to the appearance of the predicted 2.1kb vector fragment in the Southern blot of CMGSNSO DNA at an average level of approximately 1 copy/cell. Selection with 100 $\mu$ M MSX has led to an increase in copy-number to approximately 10  
30 copies/cell.

This experiment clearly indicates that pCMGS and pSV2BamGS introduced into NSO cells can be amplified by selection with MSX. No amplification of the endogenous mouse GS genes could be detected.

35

### EXAMPLE 3

In order to test the efficacy of the MSX selection



procedure described in Example 1 for the overproduction of recombinant product, the expression of B72.3 cL-chain introduced into NSO cells using GS selection was measured before and after selection with MSX. The transfection frequency was approximately  $2 \times 10^{-5}$  colonies/cell transfected for pSV2GScLc and approximately  $10^{-3}$  for pCMGScLc.

Two NSO-derived cell lines transfected with pSV2GScLc and two cell lines transfected into pCMGScLc, all secreting high levels of cL chain were first recloned by limiting dilution. The expression of cL chain from the 4 highest producing independent clones isolated were estimated by ELISA in comparison with a purified standard preparation of B72.3 cL-chain which had been quantitated by optical density ( $OD_{280}$ ) measurement. The results are shown in Table 7, together with the production rates of MSX-resistant pools derived from these cloned cell lines as described in Example 1. Pools of resistant colonies were isolated at  $40\mu\text{M}$  MSX for three of the cell lines and at  $100\mu\text{M}$  MSX for cell line C2-27.

TABLE 7

Rates of secretion of cL-chain of B72.3 from transfected NSO cell lines before and after selection for GS-gene amplification.

CELL LINE	SECRETION RATES (pg/cell/day)		
	TRANS- FECTANT	AMPLIFIED POOL	AMPLIFIED CLONE
SVGScLc-B4.24	4.6	13	20
-C2.27	0.4	3	
CMGS.cLc-9/6	1.5	0.2	
-13/7	3	9	

Thus significant increases in productivity are seen for 3 out of the 4 cell lines as a result of selection for

resistance to MSX.

The cell-pool with the highest average secretion rate, B4.24 (40 $\mu$ M) was cloned by limiting dilution and a clonal cell line was isolated which secreted cL chain at a rate of 20pg/cell/day. This represents an increase of greater than 4-fold relative to the expression level of the original transfected clone, indicating that selection for GS gene amplification does indeed lead to improved production of the desired recombinant product.

10

#### EXAMPLE 4

NSO cells were transfected with a GS-vector containing genes for both the cH and cL chains of the B72.3 antibody in order to express a complete immunoglobulin molecule from a myeloma cell line.

Plasmid pST-6 contains the cH and cL chain cDNA coding sequences, each under the control of an hCMV promoter and a SV40 poly A signal and the SV40 early-GS transcription unit from pSV2BamGS. This plasmid was linearised with Sall and introduced into NSO cells by electroporation as described above. The transfection frequency was approximately  $2 \times 10^5$  colonies/cell transfected. Transfectant lines were screened for secretion of functional antibody in a binding assay using antigen-coated plastic plates.

The amount of antibody secreted was then quantitated by an ELISA designed to detect only assembled immunoglobulin. The rates of secretion of assembled antibody for the three of the highest expressing cloned cell lines and MSX-resistant pools derived from them are shown in Table 8.

TABLE 8

CELL LINE	SECRETION RATES (pg/cell/day)		MSX* Conc. (μM)	
	TRANSFECTANT	AMPLIFIED POOL		
5				
	6A1	1.5	3.2	100
	6-11D3	1.2	0.6	80
10	6-11D5	0.4	0	80

\* MSX concentration is the concentration to which the amplified pools are resistant.

15        Thus in one of the three cell lines analysed, the expression of antibody is increased significantly by selection for GS-gene amplification. The results in Table 8 obtained using the plasmid pST-6 are markedly different from those obtained using pAb2GS described in Example 1, in  
20        which the frequency with which transfectant colonies can be isolated is markedly reduced due to promoter interference. In transfection with pAb2GS, only those few colonies in which the immunoglobulin genes upstream of the GS-gene are  
25        exceptionally poorly expressed yield sufficient GS for survival. Consequently the transfectants isolated were poor antibody producers. Using pST-6, it is possible to isolate cell lines secreting much higher levels of antibody. It will be apparent to those skilled in the art that additional alterations to the arrangement of genes on the vector will  
30        further reduce transcriptional interference with further beneficial effects of antibody-expression.

EXAMPLE 5

35        pEE690KGS was introduced into the myeloma cell line NSO by electroporation as described in Example 1. Transfectants were selected by growth on glutamine free medium (G-DMEM) after plating out in a 96 well plate. The

transfection efficiency was approximately 1 in  $10^5$  cells transfected.

Wells of the cell culture trays containing single colonies were analysed for secretion of the 90 kD fibrinolytic enzyme by fibrin agar plate assay [8]. Of 33 wells assayed, 26 were clearly positive for fibrinolytic activity. Positive transfectants were then expanded in culture for analysis of the rate of product secretion.

Cell lines isolated in this way secreted between 0.02 and 3.75 pg/cell/day as estimated by fibrin plate assay in comparison with a tissue plasminogen activator (tPA) standard. The 6 cell lines with the highest secretion rates are shown in Table 9. The fibrinolytic activity was shown to have the expected molecular weight of 90 kD by zymography, carried out according to Dodd [9].

The five cell lines with the highest secretion rates were then selected for GS gene amplification using MSX applied in the range 20 - 80  $\mu$ M, as described in Example 2. The specific production rates of MSX resistant cell-pools were determined using the fibrin plate assay and the results are shown in Table 10.

TABLE 9

Production rates of initial transfectant cell lines secreting a 90kD fibrinolytic enzyme.

	Line	pg/cell/day
	1	3.5
	5	0.75
30	9	1.4
	12	1.5
	22	1.7

TABLE 10

Production rates of cell lines secreting 90 kD  
fibrinolytic enzyme after one round of selection for vector  
amplification

Line	MSX Conc	Secretion rates	
		Pool pg/cell/day	Clone pg/cell/day
10			
1	40 $\mu$ M	5.8	4.5
5	60 $\mu$ M	1.2	
9	80 $\mu$ M	4	10.5
12	80 $\mu$ M	5.65	
15			
22	40 $\mu$ M	4.75	6
23	60 $\mu$ M	7.5	

A second round of selection for vector amplification was  
then carried out by further increasing the MSX concentration  
using the first round amplified pools as described in  
Example 2. Again specific production rates were determined  
and are shown in Table 11. This second round of selection  
led to further increases in productivity in each of the  
pooled cell lines tested, although when clones from these  
lines were analysed, the highest producers secreted  
approximately 10pg/cell/day whether the clones were isolated  
after the first or the second round of selection for GS  
amplification. This may indicate that this level of product  
secretion is saturating for these cell lines.

These results indicate that the level of expression is  
increased by selection of MSX resistant variants. A clone  
of line 9 selected for resistance to 80 $\mu$ M MSX has a  
secretion rate increased from 1.4 pg/cell/day to 10.5  
pg/cell/day after selection for GS gene amplification, an  
increase of 7.5 fold.

TABLE 11

## Specific Production Rate for 2nd Round Amplified Lines

5	Line	[MSX]	Pool pg/cell/day	Clone pg/cell/day
	1 <sup>40</sup>	100 $\mu$ M	7.75	
	9 <sup>80</sup>	300 $\mu$ M	6.5	
10	12 <sup>80</sup>	400 $\mu$ M	7.2	10
	22 <sup>40</sup>	300 $\mu$ M	6.4	8
	23 <sup>60</sup>	200 $\mu$ M	8.0	

It will be appreciated that the present invention has  
15 been described above by way of illustration only and that  
modifications in detail can be made using the skilled  
person's ordinary knowledge of the art without departing  
from the scope of the present invention.

## REFERENCES

1. Boshart, M., Weber, F., Gerhard, J., Dorsch-Hasler, K., Fleckenstein, B. and Schaffner, W., Cell, 41, 521-530, 1985.
- 5 2. Emtage, J.S., Angal, S., Doel, M.T., Harris, T.J.R., Jenkins, B., Lilley, G. and Lowe, P.A., PNAS-USA, 80, 3671-3675, 1983.
- 10 3. Mulligan, R.C. and Berg, P., PNAS-USA, 78, 2072-2076, 1981.
4. Melton, D.A., Krieg, P.A., Rebagliati, M.R., Maniatis, T., Zinn, K. and Green, M.R., Nuc. Acid Res., 12,  
15 7035, 1984.
5. Soberon, X., Covarrubias, L. and Bolivar, F., Gene, 2, 287-305, 1980.
- 20 6. Whittle, N., Adair, J., Lloyd, C., Jenkins, L., Devine, J., Schlom, J., Raubitschek, A., Colcher, D. and Bodmer, M., Protein Engineering, 1, 499-505, 1987.
7. Hayward, B.E., Hussain, A., Wilson, R.H., Lyons, A.,  
25 Woodcock, V., McIntosh, B. and Harris, T.J.R., Nuc. Acids Res., 14, 999-1008, 1986.
8. Bishop, R., Ebert, H., Gilchrist, G., Shanbron, E. and Fekete, L., Thrombos. Diathes. Haemorrhagica, 23, 202-210,  
30 1970.
9. Dodd, I., Frars, R. and Robinson, J.H., Thromb. Haemostas. 55, 94-97, 1986.

CLAIMS

1. A method for transforming a lymphoid cell line to glutamine independence which comprises:  
transforming the lymphoid cell line with a vector  
5 containing an active glutamine synthetase (GS) gene;  
growing the transformed cell line on a medium containing glutamine; and  
continuing the growth of the transformed cell line on a medium in which the glutamine is progressively depleted or  
10 on a medium lacking glutamine.
2. The method of claim 1, wherein the lymphoid cell line is a myeloma cell line.
- 15 3. The method of claim 1 or claim 2, wherein the glutamine-depleted or glutamine-free medium contains asparagine.
4. The method of any one of claims 1 to 3, wherein the  
20 lymphoid cell line is transformed with a vector containing both an active GS gene and a gene encoding another selectable marker, such as a gpt gene, or cotransformed with separate vectors encoding GS and the selectable marker respectively.
- 25 5. The method of any one of claims 1 to 4, wherein the glutamine in the medium is progressively depleted by dilution with a medium containing asparagine but lacking glutamine.
- 30 6. The method of any one of claims 1 to 5, wherein the vector used to transform the lymphoid cell line also contains an active gene coding for a protein heterologous to the lymphoid cell line.
- 35 7. The method of any one of claims 1 to 6, wherein the lymphoid cell line is co-transformed with a separate vector containing the active gene coding for the heterologous protein.



8. The method of claim 6 or claim 7, wherein the heterologous protein is an Ig-type molecule.

9. The method of any one of claims 6 to 8, wherein the  
5 GS gene comprises a relatively weak promoter and the gene (or genes) encoding the heterologous protein comprises a relatively strong promoter so that in the transformed cell lines, protein synthesis is directed preferentially to the production of the heterologous protein or peptide rather  
10 than to the production of GS.

10. A vector for transforming a lymphoid cell line to glutamine independence and to enable it to produce a heterologous protein, the vector comprising a GS gene and a  
15 gene encoding the heterologous protein, wherein the vector is arranged such that expression of the GS gene is not hindered by transcriptional interference from the promoter/enhancer transcribing the coding sequence for the heterologous protein to such an extent that glutamine-  
20 independent colonies cannot be produced.

11. The vector of claim 10, wherein the GS gene contains a relatively weak promoter, the gene encoding the heterologous protein contains a relatively strong promoter,  
25 and the promoter of the GS gene is located upstream of or directs expression in the opposite direction to that of the gene encoding the heterologous protein.

12. The vector of claim 11, wherein the combination for  
30 the weak and strong promoters is the SV40 early region and the hCMV-MIE promoters.

13. The vector of claim 10 or claim 11, wherein the vector comprises a GS gene having a weak promoter having downstream  
35 therefrom a heavy chain like gene having a strong promoter, there being on the vector a light chain like gene having a strong promoter oriented in the opposite direction to the promoters of the GS and heavy chain like genes.

40 14. The vector of claim 10 or claim 11, wherein the GS

gene has a weak promoter, the vector contains a light chain like gene and a heavy chain like gene, the heavy and light chain like genes have strong promoters, the three genes are transcribed in the same direction and the GS gene is 5 upstream of the other two genes.

1/3

# Fig. 1


Analysis by Western blotting of proteins secreted by NSO cells transfected with pAB2GS.

25µl of culture supernatant or control tissue-culture medium was run on a 10% SDS-reducing polyacrylamide gel, blotted to nitrocellulose and probed with antisera recognising human immunoglobulin chains and then with  $^{125}\text{I}$ -labelled protein A.

Lane 1: Purified B72.3 chimaeric antibody to show positions of heavy and light immunoglobulin chains.

Lanes 2-5: Culture supernatant from 4 different transfected clones.

Lane 6: Culture medium (negative control).



2/3

Fig. 2






Fig. 3



3/3

Fig. 4



# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 89/00401

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 12 N 15/00														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px;">C 12 N</td> </tr> </table> <div style="border-top: 1px solid black; padding-top: 5px; margin-top: 5px;">           Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup> </div>			Classification System	Classification Symbols	IPC <sup>4</sup>	C 12 N								
Classification System	Classification Symbols													
IPC <sup>4</sup>	C 12 N													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>9</sup></th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="border-right: 1px solid black; padding: 5px;">           WO, A, 87/04462 (CELLTECH LTD) 30 July 1987, see page 11, last paragraph; page 12, paragraphs 1,2; claim 38 cited in the application  <div style="text-align: center;">--</div> </td> <td style="padding: 5px; vertical-align: top;">1,2,4,6, 9-14</td> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="border-right: 1px solid black; padding: 5px;">           EP, A, 0255320 (INTEGRATED GENETICS, INC.) 3 February 1988, see pages 3,4  <div style="text-align: center;">--</div> </td> <td style="padding: 5px; vertical-align: top;">1,2,4,6-14</td> </tr> <tr> <td style="border-right: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="border-right: 1px solid black; padding: 5px;">           EP, A, 0244677 (DAIICHI SEIYAKI CO. LTD) 11 November 1987, see example  <div style="text-align: center;">----</div> </td> <td style="padding: 5px; vertical-align: top;">1,2,4,6, 9-14</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	WO, A, 87/04462 (CELLTECH LTD) 30 July 1987, see page 11, last paragraph; page 12, paragraphs 1,2; claim 38 cited in the application <div style="text-align: center;">--</div>	1,2,4,6, 9-14	A	EP, A, 0255320 (INTEGRATED GENETICS, INC.) 3 February 1988, see pages 3,4 <div style="text-align: center;">--</div>	1,2,4,6-14	A	EP, A, 0244677 (DAIICHI SEIYAKI CO. LTD) 11 November 1987, see example <div style="text-align: center;">----</div>	1,2,4,6, 9-14
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X	WO, A, 87/04462 (CELLTECH LTD) 30 July 1987, see page 11, last paragraph; page 12, paragraphs 1,2; claim 38 cited in the application <div style="text-align: center;">--</div>	1,2,4,6, 9-14												
A	EP, A, 0255320 (INTEGRATED GENETICS, INC.) 3 February 1988, see pages 3,4 <div style="text-align: center;">--</div>	1,2,4,6-14												
A	EP, A, 0244677 (DAIICHI SEIYAKI CO. LTD) 11 November 1987, see example <div style="text-align: center;">----</div>	1,2,4,6, 9-14												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search            18th July 1989         </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report            10. 08. 89         </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority            EUROPEAN PATENT OFFICE         </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer            M. VAN MOL  </td> </tr> </table>			Date of the Actual Completion of the International Search 18th July 1989	Date of Mailing of this International Search Report 10. 08. 89	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer M. VAN MOL								
Date of the Actual Completion of the International Search 18th July 1989	Date of Mailing of this International Search Report 10. 08. 89													
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer M. VAN MOL													

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 8900401  
SA 28351

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 04/08/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8704462	30-07-87	AU-A- 6893587	14-08-87
		EP-A- 0256055	24-02-88
		JP-T- 63502955	02-11-88
EP-A- 0255320	03-02-88	JP-A- 63126483	30-05-88
EP-A- 0244677	11-11-87	AU-A- 7151687	15-10-87
		JP-A- 63044897	25-02-88

*16.03.89, 11.11.87, 30.07.87, 02.11.88*

**THIS PAGE BLANK (USPTO)**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**